System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective

Kristen R. Nichols, Chad A. Knoderer, Elaine Cox, Michael B. Kays

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective: The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods: This was a prospective observational study of patients aged >30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results: A total of 332 patients, with a median age of 5 years (interquartile range, 1.9-12 years) and median weight of 19.9 kg (interquartile range, 11.7 - 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions: Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.

Original languageEnglish
Pages (from-to)1459-1465
Number of pages7
JournalClinical Therapeutics
Volume34
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Piperacillin
tazobactam drug combination piperacillin
Tertiary Healthcare
Vancomycin
Standard of Care
Observational Studies
Prospective Studies
Pediatrics
Weights and Measures
Therapeutics

Keywords

  • Extended infusion
  • Pediatric
  • Piperacillin-tazobactam

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy : Feasibility of Utilization From a Children's Hospital Perspective. / Nichols, Kristen R.; Knoderer, Chad A.; Cox, Elaine; Kays, Michael B.

In: Clinical Therapeutics, Vol. 34, No. 6, 06.2012, p. 1459-1465.

Research output: Contribution to journalArticle

@article{df59a1d4723d4ceeba2bc971a43c4cee,
title = "System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy: Feasibility of Utilization From a Children's Hospital Perspective",
abstract = "Background: Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective: The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods: This was a prospective observational study of patients aged >30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results: A total of 332 patients, with a median age of 5 years (interquartile range, 1.9-12 years) and median weight of 19.9 kg (interquartile range, 11.7 - 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92{\%} (n = 304) of patients. Twenty-eight patients (8{\%}) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61{\%}]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8{\%} [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions: Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.",
keywords = "Extended infusion, Pediatric, Piperacillin-tazobactam",
author = "Nichols, {Kristen R.} and Knoderer, {Chad A.} and Elaine Cox and Kays, {Michael B.}",
year = "2012",
month = "6",
doi = "10.1016/j.clinthera.2012.05.005",
language = "English",
volume = "34",
pages = "1459--1465",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "6",

}

TY - JOUR

T1 - System-Wide Implementation of the Use of an Extended-Infusion Piperacillin/Tazobactam Dosing Strategy

T2 - Feasibility of Utilization From a Children's Hospital Perspective

AU - Nichols, Kristen R.

AU - Knoderer, Chad A.

AU - Cox, Elaine

AU - Kays, Michael B.

PY - 2012/6

Y1 - 2012/6

N2 - Background: Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective: The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods: This was a prospective observational study of patients aged >30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results: A total of 332 patients, with a median age of 5 years (interquartile range, 1.9-12 years) and median weight of 19.9 kg (interquartile range, 11.7 - 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions: Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.

AB - Background: Use of extended infusions of piperacillin/tazobactam (PT) in adult patients has been described, but data in children are limited. Objective: The goal of this study was to determine the feasibility of using an extended-infusion PT dosing strategy as the standard of care in a children's hospital. Methods: This was a prospective observational study of patients aged >30 days who received PT after admission to a freestanding, tertiary care children's hospital. After institution of an extended-infusion PT dosing protocol as the standard dosing option, patients receiving PT were prospectively assessed for presence of and reasons for changes in dosing regimen. Results: A total of 332 patients, with a median age of 5 years (interquartile range, 1.9-12 years) and median weight of 19.9 kg (interquartile range, 11.7 - 37.6 kg) received PT (100 mg/kg based on piperacillin component). Extended-infusion PT was used for the duration of PT therapy in 92% (n = 304) of patients. Twenty-eight patients (8%) received a traditional infusion over 30 minutes, with 19 of 28 being changed from extended infusion and 9 of 28 being empirically prescribed traditional infusion PT. The most commonly encountered reason for not using extended infusions was coadministration of vancomycin (17 of 28 [61%]) and lack of compatibility data with PT. Dosing errors, which were voluntarily reported, were infrequent (1.8% [n = 6]). The few observed dosing errors were likely attributable to the overall ordering process at our institution, which requires ordering as the milligram per kilogram dose as total PT rather than based on piperacillin component as is commonly documented in pediatric dosing references. Conclusions: Results of this study suggest that extended-infusion PT dosing was feasible in this specific children's hospital. Ninety-two percent of patients received our institution's preferred dosing regimen; a small percentage of patients still needed to receive traditional infusion times.

KW - Extended infusion

KW - Pediatric

KW - Piperacillin-tazobactam

UR - http://www.scopus.com/inward/record.url?scp=84862149806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862149806&partnerID=8YFLogxK

U2 - 10.1016/j.clinthera.2012.05.005

DO - 10.1016/j.clinthera.2012.05.005

M3 - Article

C2 - 22657253

AN - SCOPUS:84862149806

VL - 34

SP - 1459

EP - 1465

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 6

ER -